Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin + Obinutuzumab/Rituximab in R/R FL and DLBCL
NCT02624986Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of idasanutlin in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Dec 2015; status: terminated.
02
Drugs
idasanutlin
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02624986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624986.